In vitro platforms for evaluating liver toxicity

Experimental Biology and Medicine

Volumn 239, Issue 9, 2014, Pages 1180-1191

  Bale, Shyam Sundhar ^a   Vernetti, Lawrence ^b,c   Senutovitch, Nina ^b,c   Jindal, Rohit ^a   Hegde, Manjunath ^a   Gough, Albert ^b,c   McCarty, William J ^a   Bakan, Ahmet ^c   Bhushan, Abhinav ^a   Shun, Tong Y ^b   Golberg, Inna ^a   DeBiasio, Richard ^b   Usta, O Berk ^a   Taylor, D Lansing ^b,c   Yarmush, Martin L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Drug induced liver injury; hepatotoxicity; high content screening; liver on chip; predictive modeling

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMANTADINE; AMILORIDE; ASPARTATE AMINOTRANSFERASE; ATENOLOL; BILIRUBIN; BUPIVACAINE; BUSPIRONE; CIMETIDINE; CLOTRIMAZOLE; CYTOCHROME P450; ENTACAPONE; FAMOTIDINE; FLUINDOSTATIN; FLUORESCENT DYE; GABAPENTIN; GATIFLOXACIN; GLIMEPIRIDE; IBUPROFEN; LEVOFLOXACIN; LIDOCAINE; MEVINOLIN; MONTELUKAST; PAMIDRONIC ACID; PILOCARPINE; RALOXIFENE; RANITIDINE; ROSIGLITAZONE; UNINDEXED DRUG;

ARTICLE; BIOSENSOR; CYTOTOXICITY ASSAY; ENZYME ACTIVITY; EXPERIMENTAL STUDY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; METABOLIC REGULATION; MOLECULAR BIOLOGY; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; ADVERSE DRUG REACTION; ANIMAL; BIOLOGICAL MODEL; DRUG SCREENING; EQUIPMENT; GENETIC PROCEDURES; HIGH CONTENT SCREENING; LIVER; LIVER CELL; LIVER ON CHIP; METABOLISM; METHODOLOGY; MICROFLUIDIC ANALYSIS; PATHOLOGY; PREDICTIVE MODELING; REVIEW;

DRUG-INDUCED LIVER INJURY; HEPATOTOXICITY; HIGH CONTENT SCREENING; LIVER ON CHIP; PREDICTIVE MODELING;

ANIMALS; BIOSENSING TECHNIQUES; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATOCYTES; HUMANS; LIVER; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL;

EID: 84907016464     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214531872     Document Type: Article

References (121)

1. Schuster D,Laggner C,Langer T.Why drugs fail – a study on side effects in new chemical entities.Curr Pharm Des. 2005;11:3545-59
2. Maddrey WC.Drug-induced hepatotoxicity: 2005.J Clin Gastroenterol. 2005;39:S83-9
3. Wilke RA,Lin DW,Roden DM,Watkins PB,Flockhart D,Giacomini KM,Krauss RM.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Nat Rev Drug Discov. 2007;6:904-16
4. Blomme EaG,Yang Y,Waring JF.Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.Toxicol Lett. 2009;186:22-31
5. Kaplowitz N.Acetaminophen hepatoxicity: what do we know, what don’t we know, and what do we do next?.Hepatology. 2004;40:23-6
6. Mitchell JR,Jollow DJ,Potter WZ,Davis DC,Gillette JR,Brodie BB.Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.J Pharmacol Exp Ther. 1973;187:185-94
7. Fourches D,Barnes JC,Day NC,Bradley P,Reed JZ,Tropsha A.Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chem Res Toxicol. 2010;23:171-83
8. Greaves P,Williams A,Eve M.First dose of potential new medicines to humans: how animals help.Nat Rev Drug Discov. 2004;3:226-36
9. Olson H,Betton G,Robinson D,Thomas K,Monro A,Kolaja G,Lilly P,Sanders J,Sipes G,Bracken W,Dorato M,Van Deun K,Smith P,Berger B,Heller A.Concordance of the toxicity of pharmaceuticals in humans and in animals.Regul Toxicol Pharmacol. 2000;32:56-67
10. Kaplowitz N.Idiosyncratic drug hepatotoxicity.Nat Rev Drug Discov. 2005;4:489-99
11. Roth RA, Ganey PE. Intrinsic versus Idiosyncratic drug-induced hepatotoxicity — two villains or one? 2010;332:692-7.
12. Di L.The role of drug metabolizing enzymes in clearance.Expert Opin Drug Metab Toxicol. 2014;10:379-93
13. Szabo M,Veres Z,Baranyai Z,Jakab F,Jemnitz K.Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity.PloS One. 2013;8:e59432.-e59432.
14. LeCluyse EL,Witek RP,Andersen ME,Powers MJ.Organotypic liver culture models: meeting current challenges in toxicity testing.Crit Rev Toxicol. 2012;42:501-48
15. Yi F,Liu GH,Izpisua Belmonte JC.Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy.Protein Cell. 2012;3:246-50
16. Subba Rao M,Sasikala M,Nageshwar Reddy D.Thinking outside the liver: induced pluripotent stem cells for hepatic applications.World J Gastroenterol. 2013;19:3385-96
17. Shan J,Schwartz RE,Ross NT,Logan DJ,Thomas D,Duncan SA,North TE,Goessling W,Carpenter AE,Bhatia SN.Identification of small molecules for human hepatocyte expansion and iPS differentiation.Nat Chem Biol. 2013;9:514-20
18. Zguris JC,Itle LJ,Hayes D,Pishko MV.Microreactor microfluidic systems with human microsomes and hepatocytes for use in metabolite studies.Biomed Microdevice. 2005;7:117-25
19. Emoto C,Murase S,Iwasaki K.Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.Xenobiotica. 2006;36:671-83
20. Bovenkamp MVD,Groothuis GMM,Meijer DKF,Olinga P.Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.System. 2006;45:696-703
21. Olinga P,Schuppan D.Precision-cut liver slices: a tool to model the liver ex vivo.J Hepatol. 2013;58:1-8.
22. van de Bovenkamp M,Groothuis GMM,Draaisma AL,Merema MT,Bezuijen JI,van Gils MJ,Meijer DKF,Friedman SL,Olinga P.Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu.Toxicol Sci: Official J Soc Toxicol. 2005;85:632-8
23. Vickers AEM,Saulnier M,Cruz E,Merema MT,Rose K,Bentley P,Olinga P.Organ slice viability extended for pathway characterization: an in vitro model to investigate fibrosis.Toxicol Sci: Official J Soc Toxicol. 2004;82:534-44
24. Stieger B. In vitro techniques: isolated organ perfusion, slices, cells and subcellular elements. In: Rodes J (ed.) Textbook of hepatology. MA, USA: Blackwell Publishing, 2007.
25. Gebhardt R,Hengstler JG,Muller D,Glockner R,Buenning P,Laube B,Schmelzer E,Ullrich M,Utesch D,Hewitt N,Ringel M,Hilz BR,Bader A,Langsch A,Koose T,Burger HJ,Maas J,Oesch F.New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures.Drug Metab Rev. 2003;35:145-213
26. Guillouzo A.Liver cell models in in vitro toxicology.Environ Health Perspect. 1998;106:511-32
27. LeCluyse EL.Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.Eur J Pharm Sci. 2001;13:343-68
28. Sivaraman A,Leach JK,Townsend S,Iida T,Hogan BJ,Stolz DB,Fry R,Samson LD,Tannenbaum SR,Griffith LG.A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction.Curr Drug Metab. 2005;6:569-91.
29. Hewitt NJ,Lechon MJ,Houston JB,Hallifax D,Brown HS,Maurel P,Kenna JG,Gustavsson L,Lohmann C,Skonberg C,Guillouzo A,Tuschl G,Li AP,LeCluyse E,Groothuis GM,Hengstler JG.Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.Drug Metab Rev. 2007;39:159-234
30. Dunn JC,Tompkins RG,Yarmush ML.Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration.Biotechnol Prog. 1991;7:237-45
31. Bjornsson E.Drug-induced liver injury: Hy's rule revisited.Clin Pharmacol Ther. 2006;79:521-8
32. Chiba M,Ishii Y,Sugiyama Y.Prediction of hepatic clearance in human from in vitro data for successful drug development.AAPS J. 2009;11:262-76
33. Dunn JC,Yarmush ML,Koebe HG,Tompkins RG.Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration.Faseb J. 1989;3:174-7
34. Dunn JC,Tompkins RG,Yarmush ML.Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation.J Cell Biol. 1992;116:1043-53
35. Dunn JC,Tompkins RG,Yarmush ML.Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration.Biotechnol Prog. 1991;7:237-45
36. Dunn JC,Tompkins RG,Yarmush ML.Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation.J Cell Biol. 1992;116:1043-53
37. Semler EJ,Ranucci CS,Moghe PV.Mechanochemical manipulation of hepatocyte aggregation can selectively induce or repress liver-specific function.Biotechnol Bioeng. 2000;69:359-69
38. Chen AA,Khetani SR,Lee S,Bhatia SN,Van Vliet KJ.Modulation of hepatocyte phenotype in vitro via chemomechanical tuning of polyelectrolyte multilayers.Biomaterials. 2009;30:1113-20
39. Rajagopalan P,Shen CJ,Berthiaume F,Tilles AW,Toner M,Yarmush ML.Polyelectrolyte nano-scaffolds for the design of layered cellular architectures.Tissue Eng. 2006;12:1553-63
40. Bjornsson TD,Callaghan JT,Einolf HJ,Fischer V,Gan L,Grimm S,Kao J,King SP,Miwa G,Ni L,Kumar G,McLeod J,Obach RS,Roberts S,Roe A,Shah A,Snikeris F,Sullivan JT,Tweedie D,Vega JM,Walsh J,Wrighton SA.The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.Drug Metab Dispos. 2003;31:815-32
41. Bjornsson TD,Callaghan JT,Einolf HJ,Fischer V,Gan L,Grimm S,Kao J,King SP,Miwa G,Ni L,Kumar G,McLeod J,Obach SR,Roberts S,Roe A,Shah A,Snikeris F,Sullivan JT,Tweedie D,Vega JM,Walsh J,Wrighton SA.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.J Clin Pharmacol. 2003;43:443-69
42. Grecco N,Cohen N,Warner AW,Lopez-Correa C,Truter SL,Snapir A,Piccoli SP,Wang D,Westelinck A,Hinman L,Franc MA.PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: what next?.Clin Pharmacol Therapeut. 2012;91:1035-43
43. Chu V,Einolf HJ,Evers R,Kumar G,Moore D,Ripp S,Silva J,Sinha V,Sinz M,Skerjanec A.In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.Drug Metab Dispos. 2009;37:1339-54
44. Karara AH,Edeki T,McLeod J,Tonelli AP,Wagner JA.PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.J Clin Pharmacol. 2010;50:380-91
45. Poulin P,Jones HM,Jones RD,Yates JW,Gibson CR,Chien JY,Ring BJ,Adkison KK,He H,Vuppugalla R,Marathe P,Fischer V,Dutta S,Sinha VK,Bjornsson T,Lave T,Ku MS.PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: Goals, properties of the PhRMA dataset, and comparison with literature datasets.J Pharm Sci. 2011;100:4050-73
46. Jones RD,Jones HM,Rowland M,Gibson CR,Yates JW,Chien JY,Ring BJ,Adkison KK,Ku MS,He H,Vuppugalla R,Marathe P,Fischer V,Dutta S,Sinha VK,Bjornsson T,Lave T,Poulin P.PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution.J Pharm Sci. 2011;100:4074-89
47. Ring BJ,Chien JY,Adkison KK,Jones HM,Rowland M,Jones RD,Yates JW,Ku MS,Gibson CR,He H,Vuppugalla R,Marathe P,Fischer V,Dutta S,Sinha VK,Bjornsson T,Lave T,Poulin P.PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance.J Pharm Sci. 2011;100:4090-110
48. Vuppugalla R,Marathe P,He H,Jones RD,Yates JW,Jones HM,Gibson CR,Chien JY,Ring BJ,Adkison KK,Ku MS,Fischer V,Dutta S,Sinha VK,Bjornsson T,Lave T,Poulin P.PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.J Pharm Sci. 2011;100:4111-26
49. Poulin P,Jones RD,Jones HM,Gibson CR,Rowland M,Chien JY,Ring BJ,Adkison KK,Ku MS,He H,Vuppugalla R,Marathe P,Fischer V,Dutta S,Sinha VK,Bjornsson T,Lave T,Yates JW.PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.J Pharm Sci. 2011;100:4127-57
50. Kostadinova R,Boess F,Applegate D,Suter L,Weiser T,Singer T,Naughton B,Roth A.A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.Toxicol Appl Pharmacol. 2013;268:1-16
51. Messner S,Agarkova I,Moritz W,Kelm JM.Multi-cell type human liver microtissues for hepatotoxicity testing.Arch Toxicol. 2013;87:209-13
52. Khetani SR,Bhatia SN.Microscale culture of human liver cells for drug development.Nat Biotechnol. 2008;26:120-6
53. March S,Hui EE,Underhill GH,Khetani S,Bhatia SN.Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro.Hepatology. 2009;50:920-8
54. Khetani SR,Kanchagar C,Ukairo O,Krzyzewski S,Moore A,Shi J,Aoyama S,Aleo M,Will Y.Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans.Toxicol Sci. 2013;132:107-17
55. Khetani SR,Bhatia SN.Microscale culture of human liver cells for drug development.Nat Biotechnol. 2008;26:120-6
56. Wang WW,Khetani SR,Krzyzewski S,Duignan DB,Obach RS.Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites.Drug Metab Dispos. 2010;38:1900-5
57. Andersson H,van den Berg A.Microfabrication and microfluidics for tissue engineering: state of the art and future opportunities.Lab Chip. 2004;4:98-103
58. Powers MJ, Domansky K, Kaazempur-mofrad MR, Kalezi A, Capitano A, Upadhyaya A, Kurzawski P, Wack KE, Stolz DB, Kamm R, Grif LG. A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng 2002;78:257–69.
59. Powers MJ,Janigian DM,Wack KE,Baker CS,Beer Stolz D,Griffith LG.Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor.Tissue Eng. 2002;8:499-513
60. Boyer TD,Wright TL,Manns MP,Zakim DZakim and Boyer's hepatology: a textbook of liver disease. 5th ed. Philadelphia, PA: Elsevier Saunders, 2006.Philadelphia, PA: Elsevier Saunders; 2006:
61. The liver. Arias IM, ed. West Sussex: John Wiley & Sons Ltd; 2009:
62. Lee PJ, Hung PJ and Lee LP. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture Biotechnol Bioeng 2007;97:1340-6.
63. Zhang MY,Lee PJ,Hung PJ,Johnson T,Lee LP,Mofrad MRK.Microfluidic environment for high density hepatocyte culture.Biomed Microdevice. 2008;10:117-21
64. Chan T,Yu H,Moore A,Khetani S,Tweedie DJ.Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPacTM.Drug Metab Dispos: Biol Fate Chem. 2013;41:2024-32
65. van Midwoud PM,Groothuis GM,Merema MT,Verpoorte E.Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies.Biotechnol Bioeng. 2010;105:184-94
66. Chao P,Maguire T,Novik E,Cheng KC,Yarmush ML.Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human.Biochem Pharmacol. 2009;78:625-32
67. Kidambi S,Yarmush RS,Novik E,Chao P,Yarmush ML,Nahmias Y.Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance.Proc Natl Acad Sci U S A. 2009;106:15714-9
68. Messner S,Agarkova I,Moritz W,Kelm JM.Multi-cell type human liver microtissues for hepatotoxicity testing.Arch Toxicol. 2013;87:209-13
69. Zhang MY,Lee PJ,Hung PJ,Johnson T,Lee LP,Mofrad MR.Microfluidic environment for high density hepatocyte culture.Biomed Microdevice. 2008;10:117-21
70. Domansky K,Inman W,Serdy J,Dash A,Lim MHM,Griffith LG.Perfused multiwell plate for 3D liver tissue engineering.Lab Chip. 2010;10:51-8
71. Chao P,Maguire T,Novik E,Cheng K-C,Yarmush ML.Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human.Biochem Pharmacol. 2009;78:625-32
72. Novik E,Maguire TJ,Chao P,Cheng KC,Yarmush ML.A microfluidic hepatic coculture platform for cell-based drug metabolism studies.Biochem Pharmacol. 2010;79:1036-44
73. Leigh DA,Lusby PJ,McBurney RT,Morelli A,Slawin AM,Thomson AR,Walker DB.Getting harder: cobalt(III)-template synthesis of catenanes and rotaxanes.J Am Chem Soc. 2009;131:3762-71
74. Saab L,Peluso J,Muller CD,Ubeaud-Sequier G.Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry.Cytometry Part A: J Int Soc Analytic Cytol. 2013;83:403-8
75. Kaplowitz N. Drug-induced liver injury: introduction and overview. In: Kaplowitz N, DeLeve LD (eds) Drug induced liver disease. 3rd ed. CA, USA: Elsevier, 2013.
76. Taub R.Liver regeneration: from myth to mechanism.Nat Rev Mol Cell Biol. 2004;5:836-47
77. Morgan RE,van Staden CJ,Chen Y,Kalyanaraman N,Kalanzi J,Dunn RT,2nd, Afshari CA,Hamadeh HK.A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicol Sci: Official J Soc Toxicol. 2013;136:216-41
78. Keppler D.The roles of MRP2, MRP3, and OATP1B1 and OATP1B3 in conjugated hyperbilirubinemia.Drug Metab Dispos. 2014;42:561-5
79. Kalgutkar AS,Soglia JR.Minimising the potential for metabolic activation in drug discovery.Expert Opin Drug Metab Toxicol. 2005;1:91-142
80. Guengerich FP,MacDonald JS.Applying mechanisms of chemical toxicity to predict drug safety.Chem Res Toxicol. 2007;20:344-69
81. Tujios S,Fontana RJ.Mechanisms of drug-induced liver injury: from bedside to bench.Nat Rev Gastroenterol Hepatol. 2011;8:202-11
82. Benet LZ,Broccatelli F,Oprea TI.BDDCS applied to over 900 drugs.AAPS J. 2011;13:519-47
83. Giuliano KA,Gough AH,Taylor DL,Vernetti LA,Johnston PA.Early safety assessment using cellular systems biology yields insights into mechanisms of action.J Biomol Screen. 2010;15:783-97
84. Xu JJ,Henstock PV,Dunn MC,Smith AR,Chabot JR,de Graaf D.Cellular imaging predictions of clinical drug-induced liver injury.Toxicol Sci. 2008;105:97-105
85. Liu X,LeCluyse EL,Brouwer KR,Lightfoot RM,Lee JI,Brouwer KL.Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes.J Pharmacol Exp Ther. 1999;289:1592-9
86. Liu X,Chism JP,LeCluyse EL,Brouwer KR,Brouwer KL.Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats.Drug Metab Dispos. 1999;27:637-44
87. Post PL,DeBiasio RL,Taylor DL.A fluorescent protein biosensor of myosin II regulatory light chain phosphorylation reports a gradient of phosphorylated myosin II in migrating cells.Mol Biol Cell. 1995;6:1755-68
88. Le Vee M,Gripon P,Stieger B,Fardel O.Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta.Drug Metab Dispos. 2008;36:217-22
89. Vickers AE,Fisher R,Olinga P,Dial S.Repair pathways evident in human liver organ slices.Toxicol In Vitro. 2011;25:1485-92
90. Morris MC.Fluorescent biosensors of intracellular targets from genetically encoded reporters to modular polypeptide probes.Cell Biochem Biophys. 2010;56:19-37
91. Donato MT,Jimenez N,Castell JV,Gomez-Lechon MJ.Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes.Drug Metab Dispos. 2004;32:699-706
92. Frommer WB,Davidson MW,Campbell RE.Genetically encoded biosensors based on engineered fluorescent proteins.Chem Soc Rev. 2009;38:2833-41
93. Goodchild S,Love T,Hopkins N,Mayers C.Engineering antibodies for biosensor technologies.Adv Appl Microbiol. 2005;58C:185-226
94. Ellington AD,Szostak JW.In vitro selection of RNA molecules that bind specific ligands.Nature. 1990;346:818-22
95. Szent-Gyorgyi C,Schmidt BF,Creeger Y,Fisher GW,Zakel KL,Adler S,Fitzpatrick JA,Woolford CA,Yan Q,Vasilev KV,Berget PB,Bruchez MP,Jarvik JW,Waggoner A.Fluorogen-activating single-chain antibodies for imaging cell surface proteins.Nat Biotechnol. 2008;26:235-40
96. Adams SR,Campbell RE,Gross LA,Martin BR,Walkup GK,Yao Y,Llopis J,Tsien RY.New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications.J Am Chem Soc. 2002;124:6063-76
97. Shekhawat SS,Ghosh I.Split-protein systems: beyond binary protein-protein interactions.Curr Opin Chem Biol. 2011;15:789-97
98. Zhang J,Ma Y,Taylor SS,Tsien RY.Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering.Proc Natl Acad Sci U S A. 2001;98:14997-5002
99. Ting AY,Kain KH,Klemke RL,Tsien RY.Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells.Proc Natl Acad Sci U S A. 2001;98:15003-8
100. Dooley CT,Dore TM,Hanson GT,Jackson WC,Remington SJ,Tsien RY.Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators.J Biol Chem. 2004;279:22284-93
101. Miyawaki A,Llopis J,Heim R,McCaffery JM,Adams JA,Ikura M,Tsien RY.Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin.Nature. 1997;388:882-7
102. Persechini A,Lynch JA,Romoser VA.Novel fluorescent indicator proteins for monitoring free intracellular Ca2+.Cell Calcium. 1997;22:209-16
103. Cubitt AB,Heim R,Adams SR,Boyd AE,Gross LA,Tsien RY.Understanding, improving and using green fluorescent proteins.Trends Biochem Sci. 1995;20:448-55
104. Shaner NC,Campbell RE,Steinbach PA,Giepmans BN,Palmer AE,Tsien RY.Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein.Nat Biotechnol. 2004;22:1567-72
105. Nagai T,Sawano A,Park ES,Miyawaki A.Circularly permuted green fluorescent proteins engineered to sense Ca2+.Proc Natl Acad Sci U S A. 2001;98:3197-202
106. Sakaguchi R,Endoh T,Yamamoto S,Tainaka K,Sugimoto K,Fujieda N,Kiyonaka S,Mori Y,Morii T.A single circularly permuted GFP sensor for inositol-1,3,4,5-tetrakisphosphate based on a split PH domain.Bioorg Med Chem. 2009;17:7381-6
107. Albrecht SC,Sobotta MC,Bausewein D,Aller I,Hell R,Dick TP,Meyer AJ.Redesign of genetically encoded biosensors for monitoring mitochondrial redox status in a broad range of model eukaryotes.J Biomol Screen. 2013;19:379-86
108. Wilkening S,Stahl F,Bader A.Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.Drug Metab Dispos. 2003;31:1035-42
109. van Midwoud PM,Merema MT,Verpoorte E,Groothuis GM.A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices.Lab Chip. 2010;10:2778-86
110. O'Brien PJ,Irwin W,Diaz D,Howard-Cofield E,Krejsa CM,Slaughter MR,Gao B,Kaludercic N,Angeline A,Bernardi P,Brain P,Hougham C.High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.Arch Toxicol. 2006;80:580-604
111. Vernetti L,Irwin W,Giuliano KA,Gough A,Johnston K,Taylor DLDrug efficacy, safety, and biologics discovery: emerging technologies and tools. SEaJJ Xu, ed. Hoboken, NJ: John Wiley & Sons, Inc; 2008:53-73.
112. Yang Y,Blomme EA,Waring JF.Toxicogenomics in drug discovery: from preclinical studies to clinical trials.Chem-Biol Interact. 2004;150:71-85
113. Paules R.Phenotypic anchoring: linking cause and effect.Environ Health Perspect. 2003;111:A338-9
114. Suter L,Schroeder S,Meyer K,Gautier JC,Amberg A,Wendt M,Gmuender H,Mally A,Boitier E,Ellinger-Ziegelbauer H,Matheis K,Pfannkuch F.EU framework 6 project: predictive toxicology (PredTox)-overview and outcome.Toxicol Appl Pharmacol. 2011;252:73-84
115. Gill SD,McBurney H,Schulz DL.Land-based versus pool-based exercise for people awaiting joint replacement surgery of the hip or knee: results of a randomized controlled trial.Arch Phys Med Rehabil. 2009;90:388-94
116. Chen M,Vijay V,Shi Q,Liu Z,Fang H,Tong W.FDA-approved drug labeling for the study of drug-induced liver injury.Drug Discov Today. 2011;16:697-703
117. Judson R,Richard A,Dix D,Houck K,Elloumi F,Martin M,Cathey T,Transue TR,Spencer R,Wolf M.ACToR–aggregated computational toxicology resource.Toxicol Appl Pharmacol. 2008;233:7-13
118. Lim E,Pon A,Djoumbou Y,Knox C,Shrivastava S,Guo AC,Neveu V,Wishart DS.T3DB: a comprehensively annotated database of common toxins and their targets.Nucleic Acid Res. 2010;38:D781-6
119. Liu Z,Shi Q,Ding D,Kelly R,Fang H,Tong W.Translating clinical findings into knowledge in drug safety evaluation – drug induced liver injury prediction system (DILIps).PLoS Computat Biol. 2011;7:e1002310-e1002310
120. Merlot C.Computational toxicology – a tool for early safety evaluation.Drug Discov Today. 2010;15:16-22
121. Sun H,Xia M,Austin CP,Huang R.Paradigm shift in toxicity testing and modeling.AAPS J. 2012;14:473-80